Merck bails on AD candidate verubecestat

Discussion in 'Amgen' started by anonymous, Feb 13, 2018 at 6:42 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Hey neurology, if Merck has bailed on their BACE inhibitor, what chance has the Amgen/Novartis molecule have?
     

  2. anonymous

    anonymous Guest

    Zero chance. Even if the drug works in subjects that have genetic risk, the drug won't work in the larger population of prodromal patients. Sadly, no path forward.
     
  3. anonymous

    anonymous Guest

    It does not have Sean Harpers blessing so that’s why it failed. Sean talks to God so all things will work.
     
  4. anonymous

    anonymous Guest

    Just like repatha, amgen loves to sink money into losing causes!
     
  5. anonymous

    anonymous Guest

    So often, BB has stated publicly that BACE is a genetically validated target for AD and thus we have a better chance for successful drug discovery and yet here we are, holding a rather expensive shit sandwich.
     
  6. anonymous

    anonymous Guest

    Psck9 was genetically validated too. But the impact wasn’t as great in the real world.

    Since when does a banker know science? Sean Harper has a Harvard pedigree but is complete crap.
     
  7. Junkyard Joe

    Junkyard Joe Guest

    Sean is the king. Sean picks the winners....CETP a winner....
     
  8. anonymous

    anonymous Guest

    300 million, poof!